Difference between revisions of "Fibrinogen gamma chain (TG2)"
(New page: {{subst:infobox}}) |
m |
||
(11 intermediate revisions by one other user not shown) | |||
Line 1: | Line 1: | ||
− | |||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
− | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
− | | align="center" colspan="2" bgcolor="#ffffff" | [[Image: | + | | align="center" colspan="2" bgcolor="#ffffff" | [[Image:Fibrinogen.JPG|200px|{{PAGENAME}}]] |
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
− | | | + | | Fibrinogen gamma chain |
|- | |- | ||
| Synonyms | | Synonyms | ||
Line 12: | Line 11: | ||
|- | |- | ||
| Determination type | | Determination type | ||
− | | In | + | | In vitro |
|- | |- | ||
| Source | | Source | ||
Line 18: | Line 17: | ||
|- | |- | ||
| Subcellular localization | | Subcellular localization | ||
− | | | + | | Extracellular; plasma |
|- | |- | ||
| Swissprot ID | | Swissprot ID | ||
− | | [http://au.expasy.org/uniprot/ | + | | [http://au.expasy.org/uniprot/P02679 P02679 ] |
|- | |- | ||
| Reactive glutamines | | Reactive glutamines | ||
− | | [[ | + | | [[TG2 reactive residues (Fibrinogen gamma)|Q398]] |
|- | |- | ||
| Reactive lysines | | Reactive lysines | ||
− | | | + | | K406 |
|- | |- | ||
| Substrate sequence | | Substrate sequence | ||
− | | | + | | TIGEG''Q''QHHLGGA''K''QVRPE |
+ | |||
|- | |- | ||
| Structure | | Structure | ||
− | | [http://www.rcsb.org/pdb/explore/explore.do?structureId= | + | | [http://www.rcsb.org/pdb/explore/explore.do?structureId=1FID 1FID] |
|- | |- | ||
| Surface accessibility | | Surface accessibility | ||
− | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/ | + | | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1fid.pdf ASAView] pdf |
+ | [http://gibk21.bse.kyutech.ac.jp/asaview/all/1fid.txt ASAView] txt | ||
|- | |- | ||
| Disorder prediction | | Disorder prediction | ||
Line 42: | Line 43: | ||
|- | |- | ||
| Reference | | Reference | ||
− | | [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids= | + | | [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=2902081&dopt=Abstract PMID:2902081] |
|- | |- | ||
| Notes | | Notes | ||
− | | | + | | [[Minor TG2 reactive residues (Fibrinogen gamma)|Q144, Q195, Q239, Q311]] are minor substrate sites considering modification by TG2 |
|- | |- | ||
− | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] |
Latest revision as of 11:37, 10 March 2015
Fibrinogen gamma chain (TG2) | |
---|---|
Substrate peptide name | Fibrinogen gamma chain |
Synonyms | - |
Determination type | In vitro |
Source | Homo sapiens |
Subcellular localization | Extracellular; plasma |
Swissprot ID | P02679 |
Reactive glutamines | Q398 |
Reactive lysines | K406 |
Substrate sequence | TIGEGQQHHLGGAKQVRPE |
Structure | 1FID |
Surface accessibility | ASAView pdf
ASAView txt |
Disorder prediction | IUPred |
Reference | PMID:2902081 |
Notes | Q144, Q195, Q239, Q311 are minor substrate sites considering modification by TG2 |